Core Viewpoint - Jiangsu Yaxing Anchor Chain Co., Ltd. plans to use up to 1.6 billion yuan of its idle funds to purchase financial products, aiming to enhance capital efficiency and generate greater economic benefits while ensuring normal operational liquidity [2][3]. Group 1: Financial Product Details - The company has approved the investment of 930 million yuan in the "Yuanbo Chengfeng Quantitative No. 18 Private Securities Investment Fund" [6][10]. - The fund's investment scope includes various financial instruments such as stocks, bonds, and other securities, with the ability to participate in new stock subscriptions and margin trading [8]. - The fund will have an open-ended structure starting from July 31, 2025, with management fees of 0.2% per year and custody fees of 0.01% per year [10]. Group 2: Risk Management and Oversight - The company has established internal controls to monitor the investment, including regular assessments of potential risks and audits by the internal audit department [4][5]. - The independent directors and supervisory board have the authority to oversee the use of funds and may engage professional institutions for audits if necessary [5]. Group 3: Financial Impact - The investment of 930 million yuan represents 6.24% of the company's cash holdings and 2.40% of its net assets as of March 31, 2025, indicating that it will not significantly impact the company's main business or financial condition [9].

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 鉴于潜江永安药业股份有限公司（以下简称"公司"）及子公司总计使用最高额度不超过（含）人民币 7 亿元的自有资金进行委托理财事项的授权即将到期，为提高公司自有闲置资金的利用效率，获取一定的 投资收益，公司于2025年4月28日、2025年6月24日分别召开了第七届董事会第六次临时会议及2024年年 度股东会，审议通过了《关于使用自有资金进行委托理财的议案》，同意公司及子公司总计使用最高额 度不超过（含）人民币 7.5 亿元的自有资金进行委托理财。上述额度可滚动使用，有效期自股东会审议 通过之日起不超过 12 个月，并授权公司管理层具体实施相关事宜。公司根据上述决议，择机购买了相 关理财产品，现将有关情况公告如下： 一、理财产品的主要情况 （一）2025年7月30日，公司出资3000万元，向中国银河证券股份有限公司（以下简称"银河证券"）购 买理财产品，具体情况如下： 1、产品名称：银河盛汇尊享3号集合资产管理计划 2、产品代码：ZX1003 3、产品主要投资范围： ...

Core Viewpoint - The company plans to use up to 2 billion RMB of idle self-owned funds for entrusted wealth management, focusing on high safety, good liquidity, and low-risk financial products [2][3][12]. Group 1: Overview of Entrusted Wealth Management - The purpose of entrusted wealth management is to improve the efficiency of the company's idle funds while ensuring normal operations, thereby increasing returns for the company and its shareholders [3]. - The company intends to use no more than 2 billion RMB of temporarily idle self-owned funds for entrusted wealth management, with the funds being able to circulate within this limit [4]. - The source of the entrusted wealth management funds will be the company's idle self-owned funds [5]. - The management team is authorized to handle the purchase of financial products, including selecting qualified financial institutions and products, determining purchase amounts, and signing contracts [6]. - The authorized usage period for this entrusted wealth management is valid for 12 months from the date of board approval, allowing for the funds to be reused within this limit [7]. Group 2: Approval Process - The entrusted wealth management matter has been approved by the company's fourth board meeting and the thirty-second supervisory meeting, and does not require shareholder approval [8][20]. Group 3: Risk Analysis and Control Measures - The company will conduct strict evaluations of investment products, focusing on low-risk options, while acknowledging potential market volatility [10]. - Measures to mitigate investment risks include adhering to prudent investment principles, establishing an investment ledger, and conducting regular supervision and audits [10]. Group 4: Impact on the Company - The investment in high-safety, liquid, low-risk financial products will not affect the company's normal operations or main business activities, and aims to enhance fund efficiency and shareholder returns [12][20].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 B股 900904 B股 神奇 B 股 上海神奇制药投资管理股份有限公司董事会 上海神奇制药投资管理股份有限公司 第十一届董事会第九次会议决议公告 证券代码：A 股 600613 股票简称：A 股 神奇制药 编号：2025-022 上海神奇制药投资管理股份有限公司（以下简称"公司"）第十一届董事会 第九次会议通知已于 2025 年 7 月 25 日分别以送达、传真、邮件等方式通知公司 董事、监事。会议于 2025 年 7 月 30 日以通讯表决方式召开。会议应参加表决董 事 9 人，实际参加表决董事 9 人；会议符合《公司法》及《公司章程》的有关规 定，会议及表决合法有效。经审议，会议通过如下决议： 一、审议通过《关于利用闲置资金进行委托理财的议案》 表决结果：同意 9 票，反对 0 票，弃权 0 票。 特此公告。 ...

证券代码：601801 证券简称：皖新传媒 公告编号:临 2025-027 安徽新华传媒股份有限公司 第四届监事会第三十二次（临时）会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ? 本次监事会议案获得通过。 一、 监事会会议召开情况 （一）安徽新华传媒股份有限公司（以下简称公司）第四届监事会第三十二 次（临时）会议（以下简称本次会议）的召开符合《公司法》和《公司章程》等 有关法律法规的规定，会议的召集、召开合法有效。 （二）公司于 2025 年 7 月 25 日向监事以电子邮件方式发出召开本次会议的 通知。 （三）公司于 2025 年 7 月 31 日以现场结合通讯表决方式召开本次会议。 （四）本次会议应到监事 3 人，实到监事 3 人。 （五）本次会议由监事韦薇女士主持。 重要内容提示： 二、监事会会议审议情况 ? 无监事对本次监事会的议案投反对/弃权票。 审议通过《公司关于使用闲置自有资金进行委托理财的议案》。 表决结果：3 票同意，0 票反对，0 票弃权，本议案获得通过。 监事会认为：本次公司使用不超过人 ...

证券日报网讯 7月31日晚间，神奇制药发布公告称，公司于2025年7月30日召开第十一届董事会第九次 会议，审议通过《关于利用闲置资金进行委托理财的议案》，同意公司（含子公司）使用不超过人民币 3.5亿元的闲置自有资金进行委托理财。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯 7月31日晚间，皖新传媒发布公告称，公司于2025年7月31日召开第四届董事会第三十九 次（临时）会议和第四届监事会第三十二次（临时）会议，审议通过《公司关于使用闲置自有资金进行 委托理财的议案》。在满足日常经营需求的情况下，公司拟使用不超过20亿元暂时闲置的自有资金进行 委托理财，在此额度内，资金可循环滚动使用。本议案无需提交股东大会审议批准。 ...

Meeting Overview - The sixth meeting of the fourth Supervisory Board of CATL was held on July 30, 2025, via written notice and communication, with all three supervisors present [1]. Financial Report Approval - The Supervisory Board approved the 2025 Half-Year Report and its summary, confirming that the report accurately reflects the company's situation without any false statements or omissions [1][2]. Dividend Proposal - The Supervisory Board approved the 2025 interim dividend plan, stating it aligns with regulatory guidelines and considers the company's financial status and development needs, enhancing investor satisfaction [2][3]. Stock Option Adjustment - The Supervisory Board agreed to adjust the stock option exercise price and the restricted stock grant price in accordance with the interim dividend plan, ensuring compliance with relevant regulations and protecting shareholder interests [3][4]. Fundraising Report - The Supervisory Board reviewed and approved the 2025 Half-Year Special Report on the use of raised funds, confirming compliance with regulations and no violations of shareholder interests [4]. Increase in Financial Management Quota - The Supervisory Board approved an increase in the entrusted financial management quota by up to RMB 40 billion, raising the total to RMB 80 billion for low-risk financial products, aimed at improving fund efficiency and financial returns [4].

公司于2025年4月21日分别召开第四届董事会第八次会议和第四届监事会第 七次会议，审议通过《关于2021年限制性股票激励计划首次授予部分第三个归属 期及预留授予部分第二个归属期归属条件成就的议案》，符合归属条件的首次授 予部分激励对象为145人，可归属数量为3,925,396股；符合归属条件的预留授予 部分激励对象为13人，可归属数量为219,947股。上述股票已完成归属登记手续， 并于2025年5月14日起上市流通。具体内容详见公司于2025年5月12日在中国证监 会指定创业板信息披露网站巨潮资讯网（www.cninfo.com.cn）披露的《关于2021 年限制性股票激励计划首次授予部分第三个归属期及预留授予部分第二个归属 期归属结果暨股份上市的公告》（公告编号：2025-027）。 综上所述，因公司实施股权激励股份归属，公司总股本由291,789,935股增加 至295,935,278股，注册资本由人民币291,789,935元增加至295,935,278元。 为进一步完善公司治理结构，更好地促进公司规范运作，根据《中华人民共 和国公司法》《中华人民共和国证券法》《关于新 <公司法> 配套制度规则实施 ...

Core Viewpoint - The company plans to use part of its temporarily idle self-owned funds for entrusted wealth management to improve capital efficiency and increase shareholder returns while ensuring normal operations and effective risk control [1][3]. Group 1: Purpose and Investment Strategy - The purpose of entrusted wealth management is to enhance the efficiency of fund utilization and increase returns for shareholders without affecting the company's normal operations [1]. - The company intends to invest in high-security, good liquidity products with a maturity of no more than twelve months, including wealth management products from banks, securities companies, insurance companies, futures companies, trust companies, asset management companies, and private equity funds [1][4]. Group 2: Investment Amount and Duration - The company and its subsidiaries plan to use an amount not exceeding RMB 800 million for entrusted wealth management, effective for 12 months from the date of approval by the board of directors [1][2]. Group 3: Implementation and Decision-Making Process - The company authorizes the chairman or their representative to sign relevant contracts within the approved amount and duration, including selecting qualified wealth management product issuers and defining investment amounts [2]. - The decision-making process complies with the Shenzhen Stock Exchange's rules and the company's articles of association, requiring only board approval without needing to submit to the shareholders' meeting [2]. Group 4: Risk Management and Impact on Operations - The company acknowledges potential investment risks, including market fluctuations and default risks, but emphasizes that the investment will not adversely affect daily operations and will be conducted with a focus on capital safety [3][4]. - The supervisory board supports the decision, stating that the investment will improve fund efficiency and will not harm the interests of the company or its shareholders, particularly minority shareholders [4].